The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade
Open accessAbstract
Summary Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast and lung cancer patients, CAR-T cells targeting the tumor-associated antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1) infiltrate tumors poorly and become dysfunctional. To test strategies for enhancing efficacy, we adapted the KrasLSL-G12D/+;p53f/f autochthonous model of lung adenocarcinoma to express the CAR target ROR1. Murine ROR1 CAR-T cells transferred after lymphodepletion with cyclophosphamide (Cy) transiently control tumor growth but infiltrate tumors poorly and lose function, similar to patients. Adding oxaliplatin (Ox) to the lymphodepletion regimen activates tumor macrophages to express T cell-recruiting chemokines, resulting in improved CAR-T cell infiltration, remodeling of the tumor microenvironment, and increased tumor sensitivity to anti-PD-L1. Combination therapy with Ox/Cy and anti-PD-L1 synergistically improves CAR-T mediated tumor control and survival, providing a strategy to improve CAR-T cell efficacy in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
The single-cell transcriptional landscape of mammalian organogenesis
Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D. M., Hill, A. J., Zhang, F., Mundlos, S., Christiansen, L., Steemers, F. J., et al. (2019) · Nature · doi:10.1038/s41586-019-0969-x · Cited by 4,490
Software for Computing and Annotating Genomic Ranges
Lawrence, M., Huber, W., Pagès, H., Aboyoun, P., Carlson, M., Gentleman, R., Morgan, M. T., & Carey, V. J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003118 · Cited by 4,398
NITRIC OXIDE AND MACROPHAGE FUNCTION
MacMicking, J., Xie, Q.-W., & Nathan, C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.323 · Cited by 4,211
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Scrublet: computational identification of cell doublets in single-cell transcriptomic data
Wolock, S. L., Lopez, R., & Klein, A. M. (2018) · doi:10.1101/357368 · Cited by 2,758
Scrublet: computational identification of cell doublets in single-cell transcriptomic data
Wolock, S. L., Lopez, R., & Klein, A. M. (2019) · Cell Systems · doi:10.1016/j.cels.2018.11.005 · Cited by 2,758
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Zilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H. D., Krishnan, I., Maroni, G., Meyerovitz, C. V., Kerwin, C. M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.009 · Cited by 1,475
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 894
c-Jun overexpression in CAR T cells induces exhaustion resistance
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
NR4A transcription factors limit CAR T cell function in solid tumours
Chen, J., López-Moyado, I. F., Seo, H., Lio, C.-W. J., Hempleman, L. J., Sekiya, T., Yoshimura, A., Scott-Browne, J. P., & Rao, A. (2019) · Nature · doi:10.1038/s41586-019-0985-x · Cited by 874
Intravascular staining for discrimination of vascular and tissue leukocytes
Anderson, K. G., Mayer-Barber, K., Sung, H., Beura, L., James, B. R., Taylor, J. J., Qunaj, L., Griffith, T. S., Vezys, V., Barber, D. L., et al. (2014) · Nature Protocols · doi:10.1038/nprot.2014.005 · Cited by 812
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750
Väremo, L., Nielsen, J., & Nookaew, I. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt111 · Cited by 697
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Self-citationAdusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Self-citationMoon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Hudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C., Jensen, M. C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 532
Self-citationCraddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Guo, F., Wang, Y., Liu, J., Mok, S. C., Xue, F., & Zhang, W. (2016) · Oncogene · doi:10.1038/onc.2015.139 · Cited by 468
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J. N., & Rosenberg, S. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 451
Rapid modelling of cooperating genetic events in cancer through somatic genome editing
Sánchez-Rivera, F. J., Papagiannakopoulos, T., Romero, R., Tammela, T., Bauer, M. R., Bhutkar, A., Joshi, N. S., Subbaraj, L., Bronson, R. T., Xue, W., et al. (2014) · Nature · doi:10.1038/nature13906 · Cited by 407
Emerging Cellular Therapies for Cancer
Guedan, S., Ruella, M., & June, C. H. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041407 · Cited by 386
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Jin, L., Tao, H., Karachi, A., Long, Y., Hou, A. Y., Na, M., Dyson, K. A., Grippin, A. J., Deleyrolle, L. P., Zhang, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11869-4 · Cited by 385
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
The cis-regulatory dynamics of embryonic development at single-cell resolution
Cusanovich, D. A., Reddington, J. P., Garfield, D. A., Daza, R. M., Aghamirzaie, D., Marco-Ferreres, R., Pliner, H. A., Christiansen, L., Qiu, X., Steemers, F. J., et al. (2018) · Nature · doi:10.1038/nature25981 · Cited by 363
Vascular Permeability and Drug Delivery in Cancers
Azzi, S., Hebda, J. K., & Gavard, J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00211 · Cited by 356
Srivastava, S., Salter, A. I., Liggitt, D., Yechan-Gunja, S., Sarvothama, M., Cooper, K., Smythe, K. S., Dudakov, J. A., Pierce, R. H., Rader, C., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.003 · Cited by 334
Self-citationPriceman, S. J., Tilakawardane, D., Jeang, B., Aguilar, B., Murad, J. P., Park, A. K., Chang, W.-C., Ostberg, J. R., Neman, J., Jandial, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2041 · Cited by 327
Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283309 · Cited by 266
Self-citationDuPage, M., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R., Schmidt, L. M., Crowley, D., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244
Peng, W., Ye, Y., Rabinovich, B. A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W. W., Lizée, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0712 · Cited by 222
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Srivastava, S., & Riddell, S. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701155 · Cited by 220
Self-citationAnalysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
Balakrishnan, A., Goodpaster, T., Randolph-Habecker, J., Hoffstrom, B. G., Jalikis, F. G., Koch, L. K., Berger, C., Kosasih, P. L., Rajan, A., Sommermeyer, D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2083 · Cited by 215
Self-citationCannabinoid receptor 2 mediates the retention of immature B cells in bone marrow sinusoids
Pereira, J. P., An, J., Xu, Y., Huang, Y., & Cyster, J. G. (2009) · Nature Immunology · doi:10.1038/ni.1710 · Cited by 209
Whilding, L., Halim, L., Draper, B., Parente-Pereira, A., Zabinski, T., Davies, D., & Maher, J. (2019) · Cancers · doi:10.3390/cancers11050674 · Cited by 209
Liu, G., Rui, W., Zheng, H., Huang, D., Yu, F., Zhang, Y., Dong, J., Zhao, X., & Lin, X. (2020) · European Journal of Immunology · doi:10.1002/eji.201948457 · Cited by 197
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 173
Self-citationDesign of HIV Vectors for Efficient Gene Delivery into Human Hematopoietic Cells
Yam, P. Y., Li, S., Wu, J. C., Hu, J. X., Zaia, J. A., & Yee, J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0558 · Cited by 139
van Schalkwyk, M. C., Papa, S., Jeannon, J., Urbano, T. G., Spicer, J. F., & Maher, J. F. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.144 · Cited by 126
Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A. U., & Rader, C. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021018 · Cited by 97
Self-citationDuPage, M. J. P., & Jacks, T. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.005 · Cited by 92
Nishio, N., & Dotti, G. (2015) · OncoImmunology · doi:10.4161/21505594.2014.988098 · Cited by 83
Rosito, M., Deflorio, C., Limatola, C., & Trettel, F. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4046-11.2012 · Cited by 68
Stojanovska, V., McQuade, R. M., Fraser, S., Prakash, M. D., Gondalia, S. V., Stavely, R. G., Palombo, E. A., Apostolopoulos, V., Sakkal, S., & Nurgali, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198359 · Cited by 49
Garbe, A. I., Vermeer, B., Gamrekelashvili, J., von Wasielewski, R., Greten, F. R., Westendorf, A. M., Buer, J., Schmid, R. M., Manns, M. P., Korangy, F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2383 · Cited by 42
Sinden, J. D., Allen, Y. S., Rawlins, J. N. P., & Gray, J. A. (1990) · Behavioural Brain Research · doi:10.1016/0166-4328(90)90061-i · Cited by 36
Cited by
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Programmed Cell Death Tunes Tumor Immunity
Liu, J., Hong, M., Li, Y., Chen, D., Wu, Y., & Hu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847345 · Cited by 316
A second-generation M1-polarized CAR macrophage with antitumor efficacy
Lei, A., Yu, H., Lu, S., Lu, H., Ding, X., Tan, T., Zhang, H., Zhu, M., Tian, L., Wang, X., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01687-8 · Cited by 299
Metadata
- Authors
- Srivastava, S., Furlan, S. N., Jaeger-Ruckstuhl, C. A., Sarvothama, M., Berger, C., Smythe, K. S., Garrison, S. M., Specht, J. M., Lee, S. M., Amezquita, R. A., Voillet, V., Muhunthan, V., Yechan-Gunja, S., Pillai, S. P. S., Rader, C., Houghton, A. M., Pierce, R. H., Gottardo, R., Maloney, D. G., & Riddell, S. R.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 39
- Issue
- 2
- Pages
- 193-208.e10
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3117469590
- Cited by
- 324
- References
- 63
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.